Does OBINUTUZUMAB Cause Basal cell carcinoma? 83 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 83 reports of Basal cell carcinoma have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.6% of all adverse event reports for OBINUTUZUMAB.
83
Reports of Basal cell carcinoma with OBINUTUZUMAB
0.6%
of all OBINUTUZUMAB reports
7
Deaths
24
Hospitalizations
How Dangerous Is Basal cell carcinoma From OBINUTUZUMAB?
Of the 83 reports, 7 (8.4%) resulted in death, 24 (28.9%) required hospitalization.
Is Basal cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 83 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Basal cell carcinoma?
ADALIMUMAB (1,547)
INFLIXIMAB (1,340)
METHOTREXATE (1,268)
RITUXIMAB (1,085)
ETANERCEPT (998)
ABATACEPT (852)
TOCILIZUMAB (761)
LENALIDOMIDE (685)
HYDROXYCHLOROQUINE (662)
LEFLUNOMIDE (657)
Which OBINUTUZUMAB Alternatives Have Lower Basal cell carcinoma Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE